Sanj K. Patel - 01 Apr 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHAIRMAN & CEO, Director
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
01 Apr 2024
Net transactions value
-$37,489
Form type
4
Filing time
03 Apr 2024, 17:22:45 UTC
Previous filing
11 Mar 2024
Next filing
08 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +6,482 +12% 58,998 01 Apr 2024 Direct F1
transaction KNSA Class A Common Share Tax liability $37,489 -1,903 -3.2% $19.70 57,095 01 Apr 2024 Direct
holding KNSA Class A Common Share 109,795 01 Apr 2024 Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -6,482 -25% $0.000000 19,443 01 Apr 2024 Class A Common Share 6,482 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023.